The therapeutic vaccines market size is expected to grow from US$ 1,244.94 million in 2024 to US$ 2,934.57 million by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.

Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms-such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines-are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.

Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.

End User-Based Insights

Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.

World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.